Cell membranes and membrane-embedded proteins

Cell membranes and their embedded proteins represent the most significant class of therapeutic targets in modern pharmacology, encompassing approximately 30% of the human proteome (Nature Reviews Drug Discovery, 2017). This broad category includes critical functional units such as G protein-coupled receptors (GPCRs), ion channels, transporters, and membrane-bound enzymes, which facilitate essential processes like signal transduction and molecular transport (StatPearls, 2023). Dysregulation of these membrane components is a hallmark of diverse pathologies, including oncogenic signaling in cancer, impaired ion conductance in cystic fibrosis, and neurotransmitter imbalances in psychiatric disorders (NIH, 2022). While many drugs act as specific ligands for membrane proteins, others, such as certain antibiotics and anesthetics, modulate the physical properties or integrity of the lipid bilayer itself (PubMed, 2021). From a drug development perspective, this 'target' is actually a vast landscape of distinct molecular entities, requiring high-resolution structural biology to achieve the necessary selectivity. Consequently, while the membrane system is a rich source of targets, the primary challenge remains avoiding off-target effects due to the structural similarities among related membrane protein families.

Other names

Plasma membraneBiological membranesIntegral membrane proteinsMembrane proteome

Drugs targeting membrane components operate through diverse mechanisms: small molecules and biologics act as agonists or antagonists of membrane receptors; channel blockers and modulators regulate ion flow; and certain anti-infectives physically disrupt the lipid bilayer or sequester essential membrane lipids (Nature Reviews Drug Discovery, 2017; StatPearls, 2023).